Recce Pharmaceuticals Advances in Skin Infection Trial

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd. has reached a milestone in its Phase II clinical trial for a topical gel aimed at treating acute bacterial skin infections, with over half of the required participants successfully dosed. The RECCE 327 gel has shown promising antibacterial effects and is expanding its trial sites across New South Wales and Victoria. The study, which addresses a significant and growing healthcare concern, is expected to enroll a total of 30 participants within the year.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.